Screener
Spyre Therapeutics, Inc. SYRE Free cash flow
Discontinued — last reported Q4 '24
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026. Open the filing →
- Filed
- Feb 19, 2026, 4:01 PM EST
- Fiscal year
- FY2025
- Accession
- 0001636282-26-000020
FAQ
- What is Spyre Therapeutics, Inc.'s free cash flow?
- Spyre Therapeutics, Inc. (SYRE) reported free cash flow of -$39.35M in Q4 2024.
- How has Spyre Therapeutics, Inc.'s free cash flow changed year-over-year?
- Spyre Therapeutics, Inc.'s free cash flow decreased by 26.8% year-over-year, from -$31.04M to -$39.35M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s free cash flow?
- Over 2 years (2021 to 2024), Spyre Therapeutics, Inc.'s free cash flow has grown at a 67.1% compound annual growth rate (CAGR), from -$56.34M to -$157.41M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Spyre Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude